Bookmarks
The clinical and economic burden of antibiotic use among paediatric patients with Varicella infection: a retrospective cohort analysis of real-world data in the UK
Safe People
Organisation name
Merck & Co. Inc
Organisation sector
Commercial
Applicant name(s)
Stephanie Kujawski - Chief Investigator - Merck & Co.
Inc.Victoria Banks - Corresponding Applicant - Adelphi Real WorldAmisha Patel - Collaborator - Adelphi Real WorldCaroline Casey - Collaborator - Adelphi Real WorldChristina Diomatari - Collaborator - Adelphi Real WorldM.Nabi Kanibir - Collaborator - Merck & Co.
Inc.Manjiri Pawaskar - Collaborator - Merck & Co. Inc - Pennsylvania
USAOlivia Massey - Collaborator - Adelphi Real WorldTim Holbrook - Collaborator - Adelphi Real World
Safe Projects
Project ID
CPRD468
Lay summary
Varicella (more commonly known as chicken-pox) is a common, infectious disease that usually presents in childhood. Varicella causes an itchy, red rash across large portions of the body, along with headaches, tiredness and general feelings of illness. Although the majority of varicella cases resolve on their own, some patients can develop complications requiring treatment and in the most severe cases, hospitalisation.
Technical summary
Aim: To assess and characterize the use of antibiotics for the treatment and management of varicella and its associated complications in the paediatric population in the UK.
Latest approval date
07/04/2021
Safe Data
Dataset(s) name
HES Accident and Emergency
HES Admitted Patient Care
HES Outpatient
Patient Level Index of Multiple Deprivation
Safe Setting
Access type
Release